Clinical diagnostic evaluation of HRP2 and pLDH-based rapid diagnostic tests for malaria in an area receiving seasonal malaria chemoprevention in Niger.


BACKGROUND: Rapid diagnostic tests (RDT) for malaria are common, but their performance varies. Tests using histidine-rich protein 2 (HRP2) antigen are most common, and many have high sensitivity.

Authors: Coldiron ME Assao B Langendorf C Sayinzoga-Makombe N Ciglenecki I de la Tour R Piriou E Yarima Bako M Mumina A Guindo O Page AL Grais RF
Journal Reference: Malaria journal 2019 Dec 26; 18(1); 443. doi: 10.1186/s12936-019-3079-1. Epub 2019 12 26
Histidine-rich protein 2 Malaria Niger Plasmodium lactate dehydrogenase Rapid diagnostic test

Active and adaptive case finding to estimate therapeutic program coverage for severe acute malnutrition: a capture-recapture study.


BACKGROUND: Coverage is an important indicator to assess both the performance and effectiveness of public health programs.

Authors: Isanaka S Hedt-Gauthier BL Salou H Berthé F Grais RF Allen BGS
Journal Reference: BMC health services research 2019 Dec 16; 19(1); 967. doi: 10.1186/s12913-019-4791-9. Epub 2019 12 16
Active and adaptive Capture recapture Case finding Community-based management of acute malnutrition Coverage Nigeria SQUEAC Severe acute malnutrition Therapeutic feeding program

Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin.


OBJECTIVES: Routine amoxicillin for children with uncomplicated severe acute malnutrition raises concerns of increasing antibiotic resistance.

Authors: Maataoui N Langendorf C Berthe F Bayjanov JR van Schaik W Isanaka S Grais RF Clermont O Andremont A Armand-Lefèvre L Woerther PL
Journal Reference: The Journal of antimicrobial chemotherapy 2019 Dec 10; (); Array. doi: 10.1093/jac/dkz487. Epub 2019 12 10

Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.


BACKGROUND: Residual systemic inflammation, which is associated with non-AIDS clinical outcomes, may persist despite viral suppression.

Authors: Musinguzi N Castillo-Mancilla J Morrow M Byakwaga H Mawhinney S Burdo TH Boum Y Muzoora C Bwana BM Siedner MJ Martin JN Hunt PW Bangsberg DR Haberer JE
Journal Reference: Journal of acquired immune deficiency syndromes (1999) 2019 Dec 01; 82(4); 386-391. doi: 10.1097/QAI.0000000000002148. Epub 2019 11 01

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.


BACKGROUND: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.

Authors: Mulangu S Dodd LE Davey RT Tshiani Mbaya O Proschan M Mukadi D Lusakibanza Manzo M Nzolo D Tshomba Oloma A Ibanda A Ali R Coulibaly S Levine AC Grais R Diaz J Lane HC Muyembe-Tamfum JJ Sivahera B Camara M Kojan R Walker R Dighero-Kemp B Cao H Mukumbayi P Mbala-Kingebeni P Ahuka S Albert S Bonnett T Crozier I Duvenhage M Proffitt C Teitelbaum M Moench T Aboulhab J Barrett K Cahill K Cone K Eckes R Hensley L Herpin B Higgs E Ledgerwood J Pierson J Smolskis M Sow Y Tierney J Sivapalasingam S Holman W Gettinger N Vallée D Nordwall J
Journal Reference: The New England journal of medicine 2019 Nov 27; (); Array. doi: 10.1056/NEJMoa1910993. Epub 2019 11 27

Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda


INTRODUCTION: Yellow fever is endemic in specific regions of sub-Saharan Africa and the Americas, with recent epidemics occurring on both continents.

Authors: Derick Kimathi Aitana Juan Philip Bejon Rebecca F. Grais George M. Warimwe
Journal Reference: Wellcome Open Research 2019 Nov 21; 4:182;10.12688/wellcomeopenres.15579.1
Yellow Fever Vaccination

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.


BACKGROUND: As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP.

Authors: Juan-Giner A Tchaton M Jemmy JP Soumah A Boum Y Faga EM Cisse M Grais RF
Journal Reference: Vaccine 2018 Sep 25; (); Array. doi: 10.1016/j.vaccine.2018.09.009. Epub 2018 09 25
Ebola virus disease Guinea Health-care workers Safety Surveillance rVSV vaccine

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.


Delamanid should be effective against highly resistant strains of M. tuberculosis, but uptake has been slow globally.

Authors: Seung KJ Khan P Franke MF Ahmed S Aiylchiev S Alam M Putri FA Bastard M Docteur W Gottlieb G Hewison C Islam S Khachatryan N Kotrikadze T Khan U Kumsa A Lecca L Tassew YM Melikyan N Naing YY Oyewusi L Rich M Wanjala S Yedilbayev A Huerga H Mitnick CD
Journal Reference: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Nov 02; (); Array. doi: 10.1093/cid/ciz1084. Epub 2019 11 02
antitubercular agents delamanid extensively drug-resistant tuberculosis multidrug-resistant tuberculosis

Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi).


: Despite substantial progress in antiretroviral therapy (ART) scale up, some people living with HIV (PLHIV) continue to present with advanced HIV disease, contributing to ongoing HIV-related morbidity and mortality.: We aimed to quantify population-le

Authors: Chihana ML Huerga H Van Cutsem G Ellman T Goemaere E Wanjala S Masiku C Szumilin E Etard JF Maman D Davies MA
Journal Reference: Global health action 2019 ; 12(1); 1679472. doi: 10.1080/16549716.2019.1679472. Epub 2019 11 04
ART Africa CD4 HIV population-level

Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African children.


Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC.

Authors: Ding J Coldiron ME Assao B Guindo O Blessborn D Winterberg M Grais RF Koscalova A Langendorf C Tarning J
Journal Reference: Clinical pharmacology and therapeutics 2019 Oct 25; (); Array. doi: 10.1002/cpt.1707. Epub 2019 10 25